by CCRM Australia | Dec 6, 2022
Bhavi Kadakia was an intern with CCRM Australia in 2020 and is currently employed at Novotech. In the health-care sector, translation and commercialization have traditionally been described as complex and requiring heavy investment. As such, it is imperative for...
by Stacey Johnson | Nov 25, 2022
If manufacturing is the gatekeeper to success in the cell and gene therapy space, it’s not surprising that the topic regularly comes up when industry leaders come together to discuss the future or to tackle the challenges we face in commercializing cell and gene...
by Kevin Robb | Oct 27, 2022
One of the things that sets the Till & McCulloch Meetings (TMM) apart from other conferences, in my opinion, is the priority placed on trainee development. In part, the Stem Cell Network (SCN) achieves this through their support of the Trainee Communications...
by Cal Strode | Sep 15, 2022
OmniaBio Inc., a subsidiary of CCRM, is building the largest facility of its kind in Canada, providing specialized manufacturing to the flourishing cell and gene therapy (CGT) industry. The new contract development and manufacturing organization (CDMO) will focus on...
by Cal Strode | Aug 17, 2022
Launched in June of 2015, ExCellThera is a clinical-stage biotechnology company making strides in developing robust and cost-effective processes for growing blood stem cells for therapeutic use, backed by award-winning proprietary technology. The company was founded...
by CCRM Australia | Aug 1, 2022
This post is by Harmanpreet Harmanpreet, who interned with CCRM Australia. The CCRM Australia Training Program seeks to facilitate training for the future workforce of the Australian regenerative medicine sector and includes an internship program that accepts...
Comments